Skip to main content
Premium Trial:

Request an Annual Quote

PreventionGenetics to Use GoldenHelix's VarSeq for Dx Test Offering

NEW YORK (GenomeWeb) – Golden Helix has signed an agreement with PreventionGenetics that allows the latter to implement Golden Helix's VarSeq software into its exome sequencing pipeline.

PreventionGenetics will use the solution to analyze data from an exome sequencing test for clinical diagnostics that the company is preparing to launch in mid-2015. The software streamlines the process of annotating and filtering variants from next-generation sequencing data. It features a simple user interface and scalable architecture with repeatable workflows, tools for note taking and reporting, and filter parameter prototyping.

VarSeq "will allow us to move forward with offering an exome test" by providing tools "to take abundant sequence from exome data and efficiently translate that into molecular diagnoses," Jerry Machado, a clinical molecular geneticist at PreventionGenetics, said in a statement.

Financial and other terms of the agreement were not disclosed.


The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.